ArticleJournal of advanced research2026
Mitigation of renal tubular injury by SIRT6 may improve individual outcomes in diabetic kidney disease-potential mechanisms involving epigenetic repression of inflammatory responses.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- CT-based radiogenomic prediction of ICAM1 and RAET1E as biomarkers of NK cytotoxicity in clear cell renal cell carcinoma.Frontiers in immunology · 2026Article
- Integrating single-cell analysis and machine learning algorithms to explore lactylation-related molecular mechanisms and therapeutic responses in clear cell renal cell carcinoma and identifying CDT1 as a potential biomarker.Frontiers in endocrinology · 2026Article
- The Inflammatory Cell Death in Diabetic Kidney Disease: Integrating Multifactorial Mechanisms into Novel Therapeutics.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionProgressive tubulointerstitial injury plays a critical role in the progression of diabetic kidney disease (DKD), but the epigenetic mechanisms driving this process remain largely unclear.
objectivesThis study aimed to investigate the role of the histone deacetylase SIRT6 in renal tubular epithelial cells (TECs) during DKD progression and to explore its potential as a therapeutic target.
methodsWe employed digital spatial profiling (DSP) to perform spatially resolved mRNA quantification in proximal renal tubular tissue from DKD patients. Additionally, we used genetic and pharmacological approaches in DKD mouse models to assess the effects of SIRT6 deficiency or overexpression on renal injury. Mechanistic studies included RNA-sequencing (RNA-seq) and Cleavage Under Targets and Tagmentation (CUT&Tag) sequencing, which to identify SIRT6-regulated genes and epigenetic modifications.
resultsOur findings revealed a significant reduction of SIRT6 in TECs from DKD patients, with its expression inversely correlating with disease severity. TEC-specific SIRT6 deficiency worsened renal injury and proteinuria in DKD mice, whereas SIRT6 overexpression or pharmacological activation provided renoprotection. Mechanistically, SIRT6 directly repressed Nlrp3 transcription by deacetylating histone 3 lysine 9 (H3K9), thereby inhibiting NLRP3 inflammasome activation and subsequent TEC injury.
conclusionThese findings highlight SIRT6 as a protective epigenetic factor in DKD and suggest its potential utility for disease stratification, early therapeutic intervention, and precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.